
|Articles|March 1, 2018
- Pharmaceutical Executive-03-01-2018
- Volume 38
- Issue 3
Pharmaceutical Executive, March 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
Pharma: Meet Your New Neighborsover 7 years ago
Risk Sharing, Italian Stylealmost 8 years ago
The Quest to Measure Upalmost 8 years ago
Full Disclosure Demanded for Pharma Industryalmost 8 years ago
Setting the Standard: William Soliman, ACMAalmost 8 years ago
The Law of Unintended Consequencesalmost 8 years ago
Pricing Turning Point: The Case for Innovating Pharma’s Modelalmost 8 years ago
Showdown Nears on Europe Research Incentivesalmost 8 years ago
The Personalized Genetic Profile: It’s Time to Alignalmost 8 years ago
Country Report: IndiaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Submits NDA to FDA for CagriSema
2
The End of the Rebate Era? What HR Leaders and Pharmacy Consultants Need to Know About Biosimilars
3
Eli Lilly Announces Topline Results From Phase III Trial Studying Oral GLP-1 Therapy Orforglipron
4
Senate Passes Biosecure Act
5




